Dermadeep Injection — Cost, Top Hospitals & Success Rates | MyMedicPlus

Dermadeep injections refer to the placement of injectable dermal fillers at deeper tissue planes — specifically within the deep dermis, sub-dermis, or at the supraperiosteal (above the bone) level — to restore facial volume, correct deep folds, and address structural deficits caused by ageing or congenital factors. The term 'Dermadeep' refers to a class of more viscous, cross-linked hyaluronic acid (HA) dermal fillers or calcium hydroxylapatite (CaHA) products specifically formulated for deep injection where greater lifting force and structural support are required compared to superficially placed softer fillers.

As facial ageing progresses, volume is lost from the deep fat compartments of the face (deep medial cheek fat, buccal fat, temporal fat pad), the bony skeleton undergoes resorption and remodelling (maxillary recession, orbital rim widening), and the retaining ligaments stretch, causing descent of the facial soft tissues. Dermadeep-type injection techniques address this structural volume loss at its source by replacing tissue in the deep compartments, restoring the support framework for overlying structures.

The injection technique requires precise anatomical knowledge. Products used at deep tissue planes include higher-viscosity HA fillers (Juvederm Voluma, Restylane Lyft, Belotero Intense) and CaHA (Radiesse, which additionally stimulates collagen production). These are injected using a needle or cannula in small aliquots, often with a 'bolus and massage' technique or multiple linear threads. Aspiration before injection in high-risk anatomical areas (glabellar, nasolabial, periorbital) is a critical safety step to prevent inadvertent intravascular injection. A thorough understanding of the facial danger zones — areas where deep injections carry vascular and nerve injury risk — is mandatory for practitioners performing these procedures.

Dermadeep injection techniques are used primarily for volume restoration in the mid-face (malar eminence and submalar area), where loss of deep cheek fat produces the characteristic 'hollow' or 'flattened' appearance associated with ageing. Deep injection with a viscous filler restores projection and support to the cheek, secondarily lifting the nasolabial fold and improving the transition from the lower eyelid to the cheek (tear trough junction). Temporal hollowing — caused by loss of temporal fat pad volume — is another common indication, with deep supraperiosteal injection restoring fullness to the temple.

Deep filler placement is used to address severe nasolabial folds (naso-labial creases) where superficial filler placement alone produces inadequate correction; to augment the chin and jawline to improve profile balance; to provide structural support beneath the nose for tip projection; and to treat deep marionette lines alongside superficial product. In skeletal augmentation applications, deep periosteal injection is used to provide non-surgical chin augmentation, cheekbone augmentation, and jawline definition. Volume restoration of the dorsum of the hand using deep HA or CaHA injection restores youthful appearance by reducing the visibility of tendons and veins.

Ideal candidates are adults with facial volume loss, deep folds, or structural deficits who seek non-surgical aesthetic improvement with minimal downtime. Candidates should be in good general health, have realistic expectations, and understand that deep filler results are semi-permanent, requiring maintenance injections every 12–24 months depending on the product used. Patients should disclose all medications and supplements, as anticoagulants and blood thinners (aspirin, NSAIDs, fish oil, vitamin E) increase the risk of bruising. Pausing these where medically safe for 5–7 days pre-treatment reduces bruising.

Contraindications include active skin infection or inflammation at the injection site; known allergy to hyaluronic acid or its constituents (including lidocaine, which is often pre-mixed in filler products); autoimmune conditions causing delayed hypersensitivity reactions; pregnancy and breastfeeding (no safety data); and previous permanent filler injection at the same site (risk of delayed nodule formation). Patients with active herpes labialis or a history of frequent recurrences may require antiviral prophylaxis before perioral injections. Patients with haematological disorders requiring anticoagulation need careful haematologist review and timing relative to anticoagulation management.

High-viscosity cross-linked hyaluronic acid fillers (Juvederm Voluma XC, Restylane Lyft, Teosyal RHA4) are specifically engineered for deep tissue placement, offering high G-prime (elastic modulus — resistance to deformation) values that provide lifting capacity and structural support. These products last 12–24 months in deep tissue planes due to the slower enzymatic degradation in avascular compartments. The key advantage of HA fillers is reversibility — hyaluronidase enzyme can rapidly dissolve HA in the event of vascular compromise or patient dissatisfaction.

Calcium hydroxylapatite (Radiesse) is a longer-lasting option (12–18 months for volume; collagen stimulation effect can persist 18–24 months), used for deep cheek volumisation, hand rejuvenation, and jawline definition. It is not reversible with hyaluronidase. Poly-L-lactic acid (Sculptra) is a biostimulatory product requiring multiple sessions (typically 2–3 over 3 months) that stimulates collagen production for gradual, natural-looking volume restoration — particularly suited to overall facial biostimulation rather than focal deep augmentation. A full facial volumisation approach — often called the 'liquid facelift' — combines deep structural injection at multiple anatomical sites with superficial refinement injections to achieve comprehensive rejuvenation. The layered injection strategy for the midface — combining a small volume of high-G-prime filler in the deep fat compartments with a low-G-prime filler for more superficial soft tissue support — provides natural-looking volumisation that respects the anatomical distribution of facial fat pads lost during ageing, producing results that appear refreshed rather than surgically altered.

Deep filler injection for mid-face volumisation produces immediate, visible improvement in facial contour and projection, with results lasting 12–24 months. The results appear natural when the correct product is chosen for the correct tissue plane and injected in the correct quantity. Multiple clinical studies and registry data from large aesthetic medicine databases confirm patient satisfaction rates of 85–95% for cheek and mid-face volumisation with appropriate HA fillers. The 'lifted' appearance achieved by restoring deep fat compartment volume secondarily addresses early jowl formation, deepened nasolabial folds, and lower lid hollowing — without the recovery associated with surgical approaches.

Dermadeep techniques using CaHA (Radiesse) also stimulate neocollagenesis — production of new collagen fibres in the dermis — providing a dermal quality improvement that persists after the filler itself has resorbed. This dual aesthetic (immediate filling + long-term collagen stimulation) is unique to this class of product. As a non-surgical treatment, dermadeep injection avoids general anaesthesia, surgical incisions, and the recovery period of surgical facelift, making it accessible for patients who are not surgical candidates or who prefer gradual, reversible aesthetic enhancement.

Bruising is the most common side effect, affecting 15–30% of patients, typically resolving within 7–10 days. Swelling at the injection site is expected for 24–72 hours. The most serious complication of dermal filler injection — particularly at deep tissue planes near facial arteries — is vascular occlusion: accidental intravascular injection or external compression of a vessel by filler product causing ischaemia. The facial arteries at risk include the ophthalmic artery, supraorbital artery, and angular artery, where occlusion can result in skin necrosis or, most critically, blindness from central retinal artery occlusion. This catastrophic complication is extremely rare (estimated incidence 1 in 100,000–200,000 injections for blindness) but requires immediate treatment with hyaluronidase for HA fillers.

Delayed hypersensitivity reactions presenting as nodules, swelling, and erythema can occur weeks to months after injection (so-called 'filler nodules' or delayed inflammatory reactions), sometimes triggered by remote infection or dental procedures. These are managed with hyaluronidase (for HA), intralesional steroid, and in some cases antibiotics (if biofilm infection is suspected). Tyndall effect — a blue-grey skin discolouration — results from superficial placement of HA filler in the dermal papillae and is avoided by maintaining appropriate injection depth. Product migration from the injection site is more common with soft, low-viscosity HA fillers when placed in areas of high muscle movement.

Following deep filler injection, patients should apply ice packs (wrapped in cloth) to treated areas in 10-minute intervals for the first 24 hours to reduce swelling. Avoid vigorous facial massage, high-impact exercise, extreme heat (saunas, hot yoga), and alcohol for 24–48 hours as these increase swelling and bruising. Avoid direct sun exposure on treated areas for 2 weeks. Makeup can be applied carefully from the following day using clean brushes to avoid introducing bacteria into fresh injection sites.

A 2-week follow-up appointment allows the treating clinician to assess the final result once all swelling has resolved, to perform any touch-up injections needed for symmetry or additional volume, and to address any concerns. For CaHA and poly-L-lactic acid products, results continue to improve over 4–8 weeks as collagen stimulation progresses. Patients should return promptly if they experience unusual pain, blanching of the skin (possible vascular compromise), or signs of infection at any injection site. Product should be maintained with repeat injections every 12–18 months to preserve results, though the interval lengthens with each treatment in some patients due to cumulative collagen stimulation effects.

The cost of deep dermal filler injection depends on the product used, the volume required, the number of treatment areas, and the expertise of the injector. In the United States, a single syringe (1 mL) of high-viscosity HA filler for deep cheek volumisation costs USD 700–1,200; full mid-face volumisation typically requiring 2–4 syringes costs USD 1,400–4,800. CaHA (Radiesse) costs USD 800–1,100 per syringe. Full facial rejuvenation ('liquid facelift') using multiple products costs USD 3,000–8,000 per session. In the United Kingdom, comparable treatments cost GBP 400–800 per mL of HA filler, with full-face treatments costing GBP 2,000–6,000.

Medical tourism for injectable aesthetic treatments offers considerable savings. Aesthetic medicine clinics in India, Thailand, Turkey, and Mexico staffed by trained aesthetic physicians or dermatologists offer deep filler treatments at 40–70% less than US costs. A full mid-face volumisation using imported branded HA fillers (Juvederm, Restylane) costs USD 300–800 in India; USD 400–900 in Thailand; USD 350–700 in Turkey. Patients should verify the authenticity of the filler product (counterfeit fillers are a serious concern in some markets) and the qualifications and experience of the injector before proceeding.

Surgical approaches — facelift (rhytidectomy) with or without fat grafting — provide more durable structural lifting and volume restoration than injectable fillers, with results lasting 7–10 years. For patients with significant skin laxity and jowl formation, surgical intervention may be more appropriate than repeated filler treatment. Fat grafting (structural fat grafting — lipostructure) uses the patient's own fat harvested by liposuction and reinjected in multiple micro-aliquots, providing a natural, biocompatible volumising filler with the potential for permanent results in successful fat grafts.

Non-invasive skin tightening devices — high-intensity focused ultrasound (HIFU, Ultherapy) and radiofrequency (Thermage, Morpheus8) — stimulate collagen and elastin production through deep heating without injection, providing mild to moderate lifting in appropriately selected patients. Thread lifts using absorbable polydioxanone (PDO) or poly-L-lactic acid (PLLA) sutures provide immediate mechanical lifting and subsequent collagen stimulation as an intermediate option between injectables and surgery. For patients with mild volume loss and good skin quality, optimising skincare with retinoids, antioxidants, and growth factor serums alongside lifestyle changes (UV protection, hydration, nutrition) produces meaningful long-term skin quality improvement.